Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin

Macías, Juan; Del Valle, José; Rivero, Antonio; Mira, José A.; Camacho, Ángela; Merchante, Nicolás; Pérez-Camacho, Inés; Neukam, Karin; Rivero-Juárez, Antonio; Mata, Rosario; Torre-Cisneros, Julián; Pineda, Juan A.
October 2010
Journal of Antimicrobial Chemotherapy (JAC);Oct2010, Vol. 65 Issue 10, p2204
Academic Journal
Objectives: To evaluate the changes in liver stiffness measurement (LSM) in patients infected by hepatitis C virus (HCV) under pegylated interferon (Peg-IFN) plus ribavirin therapy.


Related Articles

  • Characterization of Hepatitis C Virus genotype 3a Hypervariable region 1 in patients achieved rapid virological response to alpha interferon and Ribavirin Combination therapy. Akram, Madiha; Idrees, Muhammad; Hussain, Abrar; Afzal, Samia; Ilyas, Muhammad; Zafar, Shamail; Aftab, Mahwish; Badar, Sadaf; Khubaib, Bushra // Virology Journal;2011, Vol. 8 Issue 1, p253 

    Background: Hepatitis C virus roots a chronic liver disease. Currently approved treatment strategy includes administration of alpha interferon and ribavirin combined therapy for 24-48 weeks. One of the predictor of sustained virological response is an early virological response to treatment...

  • Sustained Virological Response to Interferon Plus Ribavirin Reduces Non–Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus. Berenguer, Juan; Rodríguez, Elena; Miralles, Pilar; Von Wichmann, Miguel A.; López-Aldeguer, José; Mallolas, Josep; Galindo, María J.; Van Den Eynde, Eva; Téllez, María J.; Quereda, Carmen; Jou, Antoni; Sanz, José; Barros, Carlos; Santos, Ignacio; Pulido, Federico; Guardiola, Josep M.; Ortega, Enrique; Rubio, Rafael; Jusdado, Juan J.; Montes, María L. // Clinical Infectious Diseases;Sep2012, Vol. 55 Issue 5, p728 

    We observed that eradication of hepatitis C virus in patients coinfected with human immunodeficiency virus (HIV) was associated not only with a reduction in liver-related complications and mortality but also with a reduction in the progression of HIV infection and mortality not related to liver...

  • Response to Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis C in Hispanics Compared to Non-Hispanic Whites. Yu, Stanley; Douglass, Jeffrey M.; Qualls, Clifford; Arora, Sanjeev; Dunkelberg, Jeffrey C. // American Journal of Gastroenterology;Jul2009, Vol. 104 Issue 7, p1686 

    OBJECTIVES:Ethnicity has been shown to play an important role in hepatitis C virus (HCV) treatment response. However, few studies have examined the treatment response of Hispanics to combination therapy with pegylated interferon and ribavirin. The aim of this study was to compare the treatment...

  • The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. Oze, Tsugiko; Hiramatsu, Naoki; Yakushijin, Takayuki; Mochizuki, Kiyoshi; Imanaka, Kazuho; Yamada, Akira; Oshita, Masahide; Kaneko, Akira; Hagiwara, Hideki; Mita, Eiji; Ito, Toshifumi; Nagase, Toshihiko; Inui, Yoshiaki; Hijioka, Taizo; Tamura, Shinji; Yoshihara, Harumasa; Hayashi, Eijiro; Imai, Yasuharu; Kato, Michio; Hosui, Atsushi // Journal of Gastroenterology;Jul2011, Vol. 46 Issue 7, p944 

    Background: Which patients with hepatitis C virus (HCV) genotype 1 can benefit from extended treatment with pegylated interferon (Peg-IFN) plus ribavirin is unknown, although the overall sustained virologic response (SVR) rate has been shown to improve in patients with a late virologic response...

  • Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin. Fung, James; Ching-Lung Lai; Hung, Ivan; Young, John; Cheng, Charles; Wong, Danny; Man-Fung Yuen // Journal of Infectious Diseases;9/15/2008, Vol. 198 Issue 6, p808 

    Background. To date, no study has evaluated pegylated interferon for the treatment of chronic infection with hepatitis C virus (HCV) genotype 6. We aimed to determine the efficacy of pegylated interferon plus ribavirin for treating infection with genotype 6 versus genotype 1. Methods. Forty-two...

  • Viral Hepatitis C Gets Personal - The Value of Human Genomics to Public Health. Zhang, L.; Gwinn, M.; Hu, D.J. // Public Health Genomics;Aug2013, Vol. 16 Issue 4, p192 

    About 180 million people worldwide are chronically infected with hepatitis C virus (HCV), with 3-4 million newly infected each year. Only 15-25% of acute HCV infections clear spontaneously, and the remainder persists as chronic HCV infection. More than 350,000 people die every year from...

  • Predictive Factors for Sustained Virological Response after Treatment with Pegylated Interferon α-2a and Ribavirin in Patients Infected with HCV Genotypes 2 and 3. Niederau, Claus; Mauss, Stefan; Schober, Andreas; Stoehr, Albrecht; Zimmermann, Tim; Waizmann, Michael; Moog, Gero; Pape, Stefan; Weber, Bernd; Isernhagen, Konrad; Sandow, Petra; Bokemeyer, Bernd; Alshuth, Ulrich; Steffens, Hermann; Hüppe, Dietrich // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Background: Previous trials have often defined genotype 2 and 3 patients as an “easy to treat” group and guidelines recommend similar management. Aims: The present study looks for differences between the two genotypes and analyzes predictive factors for SVR. Methods: Prospective,...

  • HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. C Nelson Hayes // Gut;Feb2011, Vol. 60 Issue 2, p261 

    BACKGROUND AND AIMS: A number of recent studies have shown that human polymorphisms near the IL28B type III interferon (IFNλ) gene influence the response to peg-interferon plus ribavirin combination therapy for infection with chronic hepatitis C virus (HCV). Viral polymorphisms, including...

  • Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection. McHutchison, John G.; Lawitz, Eric J.; Shiffman, Mitchell L.; Muir, Andrew J.; Galler, Greg W.; McCone, Jonathan; Nyberg, Lisa M.; Lee, William M.; Ghalib, Reem H.; Schiff, Eugene R.; Galati, Joseph S.; Bacon, Bruce R.; Davis, Mitchell N.; Mukhopadhyay, Pabak; Koury, Kenneth; Noviello, Stephanie; Pedicone, Lisa D.; Brass, Clifford A.; Albrecht, Janice K.; Sulkowski, Mark S. // New England Journal of Medicine;8/6/2009, Vol. 361 Issue 6, p580 

    Background: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. Methods: At 118 sites, patients who had HCV genotype 1...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics